Latest Headlines
-
JHS CEO Chris Preti Receives 2026 Person Of Influence Award
2/12/2026
Spokane, WA. - The Spokane Journal of Business named Chris Preti, CEO of Jubilant HollisterStier (JHS), as one of its 2026 People of Influence.
-
AGC Biologics Seattle Site Now Certified To Manufacture Biologics For Largest Pharmaceutical Market In South America
2/5/2026
AGC Biologics’ Seattle site earned Anvisa GMP certification, enabling biologics and biosimilars produced there to enter Brazil’s expanding pharmaceutical market and strengthening the facility’s global regulatory track record.
-
Eurofins CDMO Alphora Joins International Consortium Project To Advance Next Generation ADC Expression Platform
2/5/2026
As part of this initiative, Eurofins CDMO Alphora (Canada) is collaborating with Daresbury Proteins Ltd. (UK) to contribute its development and manufacturing expertise to the NextGen ADC Platform: Engineering High Yielding Expression Vectors and Peptide Linker Tags for Advanced ADC Production initiative.
-
Kindeva Announces Leadership Transition To Drive Strategic Growth
1/16/2026
Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, today announced a series of planned leadership transitions designed to position the company for accelerating growth in its core businesses focused on parenteral and inhaled drug delivery.
-
Cellares Expands Global Footprint With New European IDMO Smart Factory In Leiden
1/16/2026
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity.
-
Rakuten Medical And LOTTE Biologics Sign Manufacturing Agreement To Support Biopharmaceuticals In Global Oncology Program
1/14/2026
Rakuten Medical, Inc. and LOTTE Biologics today announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P. Morgan Healthcare Conference in San Francisco to strengthen Rakuten Medical’s production capabilities for its innovative oncology therapy, Alluminox® platform-based photoimmunotherapy.
-
CDMO GBI Biomanufacturing Announces New President
1/6/2026
GBI Biomanufacturing, a U.S.-based biopharmaceutical CDMO providing integrated development and cGMP manufacturing services for complex biologics, today announced that Jesse McCool, Ph.D. has been appointed President.
-
Samsung Biologics Expands U.S. Manufacturing Capabilities With Strategic Acquisition Of Human Genome Sciences From GSK
12/22/2025
This strategic move secures Samsung Biologics’ first U.S.-based manufacturing site, a significant expansion of the company’s global footprint and its long-term commitment to the U.S. market.
-
Sanofi Toronto Equipment Assets Auction Announced For January 2026
12/19/2025
Federal Equipment Company, a trusted global provider of surplus pharmaceutical and chemical processing equipment, announced it will conduct a two-day online auction on behalf of Sanofi featuring quality process and laboratory equipment surplus to the company’s ongoing operational needs.
-
Alnylam Announces $250M Investment To Expand U.S. Manufacturing Capacity In Massachusetts For RNAi Therapeutics
12/18/2025
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry’s first fully dedicated, proprietary, siRNA enzymatic-ligation manufacturing facility. This investment is expected to meaningfully expand capacity, significantly reduce production costs, and position Alnylam to support future launches across its growing pipeline of potential new medicines.